A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...